A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Vesatolimod (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 12 Apr 2017 Planned End Date changed from 1 Sep 2018 to 1 May 2019.
- 12 Apr 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Apr 2019.
- 12 Apr 2017 Status changed from not yet recruiting to recruiting.